Aviezer David 4
4 · Protalix BioTherapeutics, Inc. · Filed Feb 26, 2010
Insider Transaction Report
Form 4
Aviezer David
DirectorPresident & CEO
Transactions
- Award
Stock Options (Right to Buy)
2010-02-25+250,000→ 250,000 totalExercise: $6.90Exp: 2020-02-25→ Common Stock (250,000 underlying)
Footnotes (2)
- [F1]The options vest quarterly, in 12 equal tranches over a three-year period, commencing upon the U.S. Food and Drug Administration's marketing approval of taliglucerase alfa, if at all, and are subject to accelerated vesting upon a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan.
- [F2]Does not include options to purchase 326,267 shares of common stock at an exercise price equal to $0.12 per share that expire on December 8, 2013, options to purchase 977,296 shares of common stock at an exercise price equal to $0.972 per share that expire on September 10, 2016, options to purchase 600,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018, and options to purchase 100,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019.